LIDEX
LOE ApproachingNDATOPICALCREAM
Approved
Jun 1971
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LIDEX is a topical cream formulation approved in 1971 for dermatological indications. The generic name and mechanism of action are not publicly documented in this dataset. This is a legacy NDA product currently owned by Alvogen.
LOE Approaching
Product is in late-stage lifecycle with approaching loss of exclusivity, likely indicating a small, defensive commercial team focused on margin preservation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LIDEX currently has zero linked open positions, reflecting its mature, declining stage. Working on this product offers limited growth opportunity and is typically viewed as a cost-management or portfolio maintenance role rather than a career accelerator.
Brand ManagerField Sales Representative
Worked on LIDEX at Alvogen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.